Reversing endometrial hyperplasia with levonorgestrel-intrauterine system: a Cochrane review
December 8th 2020In the largest meta-analysis study to date, researchers find that a levonorgestrel-intrauterine system (LNG-IUS) used for 3 to 6 months is likely more effective than non‐intrauterine progestogens for reversing endometrial hyperplasia (EH).
Sexual health after cancer treatment
December 4th 2020The vast majority of cancer survivors reported that they experience sexual side effects after chemotherapy, radiation and other cancer treatments according to the results of a survey presented at the annual meeting of the American Society for Radiation Oncology.
Vertigo risk factors in perimenopausal women
December 3rd 2020It has yet to be fully elucidated why postmenopausal women have a higher prevalence of benign paroxysmal positional vertigo (BPPV); however, the sudden decrease in estrogen during menopause can cause a rapid decrease in estrogen receptors, which may disturb otoconial metabolism and thus, increase the prevalence of BPPV.
Novel engineered cytokine plus pembrolizumab to treat ovarian cancer
November 24th 2020Heavily pretreated ovarian cancer patients who received a combination therapy of a novel engineered interleukin-2 (IL-2) cytokine plus pembrolizumab achieved an acceptable safety profile, according to a small cohort of an ongoing phase 1/2 trial.